BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes

Dow Jones

Yesterday

By Denny Jacob

BioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines.

The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period.

Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros.

The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year.

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin.

BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

March 10, 2025 07:39 ET (11:39 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/news/2518247060"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2518247060\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2518247060?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-10 19:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518247060","market":"other","top_or_hot":-1,"title":"BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. \n</p>\n<p>\n  The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period. \n</p>\n<p>\n  Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros. \n</p>\n<p>\n  The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year. \n</p>\n<p>\n  \"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin. \n</p>\n<p>\n  BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>BioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech SE 4Q Profit Declines as Demand for Covid-19 Vaccines Wanes\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-10 19:39</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Denny Jacob \n</p>\n<pre>\n \n</pre>\n<p>\n<a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. \n</p>\n<p>\n  The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period. \n</p>\n<p>\n  Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros. \n</p>\n<p>\n  The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year. \n</p>\n<p>\n  \"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin. \n</p>\n<p>\n  BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Denny Jacob at denny.jacob@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2025 07:39 ET (11:39 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2518247060","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518247060","pubTimestamp":1741606740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"BioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines.The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros , or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros , or 1.88 euros a share, in the prior-year period.Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros.The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year.\"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin.BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"随着Covid-19疫苗需求减弱，BioNTech SE第四季度利润下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1},"content_text":"By Denny Jacob \n\n\n \n\n\nBioNTech SE posted a smaller profit in its latest quarter as sales slumped under reduced demand for its Covid-19 vaccines. \n\n\n  The German developer of RNA vaccines and immunotherapies logged a profit of 259.5 million euros ($281.1 million), or 1.08 euros a share, for the fourth quarter, compared to 457.9 million euros ($496.1 million), or 1.88 euros a share, in the prior-year period. \n\n\n  Revenue declined to 1.19 billion euros from 1.48 billion euros. Analysts polled by FactSet expected 1.09 billion euros. \n\n\n  The top-line decline reflects lower sales of the company's Covid-19 vaccines due to reduced market demand throughout the year. \n\n\n  \"We expect 2025 to be a data-rich year with multiple important updates from our priority programs,\" said Chief Executive Ugur Sahin. \n\n\n  BioNTech forecast revenue between 1.7 billion euros and 2.2 billion euros in 2025. Analysts polled by FactSet expected 2.54 billion euros. \n\n\n \n\n\n  Write to Denny Jacob at denny.jacob@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2025 07:39 ET (11:39 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}